Among the various approaches explored, dual PPAR-α/γ agonists yielded the most promising results, demonstrating therapeutic potential in the treatment of diabetes, in cardiovascular protection, and in the management of dyslipidemias. This evidence concerns the gene PPARA and diabetes mellitus.